Vertex pauses Moderna-partnered cystic fibrosis trial, takes $379M hit tied to separate program
Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis trial over a tolerability issue, while reporting a separate impairment charge of $379 million tied to an earlier discontinuation.
Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis trial over a tolerability issue, while reporting a separate impairment charge of $379 million tied to an earlier discontinuation.
